{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T16:26:57Z","timestamp":1769272017315,"version":"3.49.0"},"reference-count":122,"publisher":"Cambridge University Press (CUP)","issue":"1","license":[{"start":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T00:00:00Z","timestamp":1709510400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Can. J. Neurol. Sci."],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>ABSTRACT:<\/jats:title>\n                  <jats:p>\n                    PET imaging is increasingly recognized as an important diagnostic tool to investigate patients with cognitive disturbances of possible neurodegenerative origin. PET with 2-[\n                    <jats:sup>18<\/jats:sup>\n                    F]fluoro-2-deoxy-D-glucose ([\n                    <jats:sup>18<\/jats:sup>\n                    F]FDG), assessing glucose metabolism, provides a measure of neurodegeneration and allows a precise differential diagnosis among the most common neurodegenerative diseases, such as Alzheimer\u2019s disease, frontotemporal dementia or dementia with Lewy bodies. PET tracers specific for the pathological deposits characteristic of different neurodegenerative processes, namely amyloid and tau deposits typical of Alzheimer\u2019s Disease, allow the visualization of these aggregates\n                    <jats:italic>in vivo<\/jats:italic>\n                    . [\n                    <jats:sup>18<\/jats:sup>\n                    F]FDG and amyloid PET imaging have reached a high level of clinical validity and are since 2022 investigations that can be offered to patients in standard clinical care in most of Canada.\n                  <\/jats:p>\n                  <jats:p>This article will briefly review and summarize the current knowledge on these diagnostic tools, their integration into diagnostic algorithms as well as perspectives for future developments.<\/jats:p>","DOI":"10.1017\/cjn.2024.31","type":"journal-article","created":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T02:56:04Z","timestamp":1709520964000},"page":"26-38","source":"Crossref","is-referenced-by-count":5,"title":["PET Imaging in Dementia: Mini-Review and Canadian Perspective for Clinical Use"],"prefix":"10.1017","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2538-3074","authenticated-orcid":false,"given":"Freimut","family":"Juengling","sequence":"first","affiliation":[{"name":"University of Alberta"},{"name":"Cross Cancer Institute"},{"name":"University of Bern"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Wuest","sequence":"additional","affiliation":[{"name":"Cross Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Schirrmacher","sequence":"additional","affiliation":[{"name":"Cross Cancer Institute"},{"name":"University of Alberta"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Abele","sequence":"additional","affiliation":[{"name":"University of Alberta"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Thiel","sequence":"additional","affiliation":[{"name":"Lady Davis Institute for Medical Research, McGill University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Paul","family":"Soucy","sequence":"additional","affiliation":[{"name":"Montr\u00e9al Neurological Institute, McGill University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Camicioli","sequence":"additional","affiliation":[{"name":"University of Alberta"},{"name":"University of Alberta"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Garibotto","sequence":"additional","affiliation":[{"name":"University Hospitals of Geneva"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2024,3,4]]},"reference":[{"key":"S0317167124000313_ref51","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jalz.2019.02.005","article-title":"Comparison of 18F-florbetaben quantification results using the standard centiloid, MR-based, and MR-less CapAIBL\u00ae approaches: validation against histopathology","volume":"15","author":"Dor\u00e9","year":"2019","journal-title":"Alzheimer\u2019s Dement"},{"key":"S0317167124000313_ref105","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.nucmedbio.2010.11.004","article-title":"Radiopharmacological evaluation of 6-deoxy-6-[18F]fluoro-D-fructose as a radiotracer for PET imaging of GLUT5 in breast cancer","volume":"38","author":"Wuest","year":"2011","journal-title":"Nucl Med Biol"},{"key":"S0317167124000313_ref121","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s43587-022-00204-0","article-title":"Biomarker modeling of Alzheimer\u2019s disease using PET-based Braak staging","volume":"2","author":"Therriault","year":"2022","journal-title":"Nat Aging"},{"key":"S0317167124000313_ref12","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.neurobiolaging.2016.03.033","article-title":"Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer\u2019s disease in the context of a structured 5-phase development framework","volume":"52","author":"Garibotto","year":"2017","journal-title":"Neurobiol Aging"},{"key":"S0317167124000313_ref66","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s00259-020-05118-w","article-title":"Clinical validity of increased cortical uptake of [(18)F]flortaucipir on PET as a biomarker for Alzheimer\u2019s disease in the context of a structured 5-phase biomarker development framework","volume":"48","author":"Wolters","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"S0317167124000313_ref85","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1097\/00001756-200210280-00022","article-title":"Mapping gray matter loss with voxel-based morphometry in mild cognitive impairment","volume":"13","author":"Ch\u00e9telat","year":"2002","journal-title":"Neuroreport"},{"key":"S0317167124000313_ref45","unstructured":"45. Search: Clinical Trials using SV2A-PET in Canada. https:\/\/clinicaltrials.gov\/search?locStr=Canada&country=Canada&term=SV2A. Accessed February 2, 2024."},{"key":"S0317167124000313_ref53","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1007\/s00259-020-05174-2","article-title":"Visual assessment of [18F]flutemetamol PET images can detect early amyloid pathology and grade its extent","volume":"48","author":"Collij","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"S0317167124000313_ref11","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/ene.13728","article-title":"European association of nuclear medicine and European academy of neurology recommendations for the use of brain (18) F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus","volume":"25","author":"Nobili","year":"2018","journal-title":"Eur J Neurol"},{"key":"S0317167124000313_ref28","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.2174\/1567205018666210212162443","article-title":"A comparison of two statistical mapping tools for automated brain FDG-PET analysis in predicting conversion to Alzheimer\u2019s disease in subjects with mild cognitive impairment","volume":"17","author":"Garibotto","year":"2020","journal-title":"Curr Alzheimer Res"},{"key":"S0317167124000313_ref107","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1021\/acschemneuro.9b00144","article-title":"First-in-human brain imaging of [18F]TRACK, a PET tracer for tropomyosin receptor kinases","volume":"10","author":"Bailey","year":"2019","journal-title":"ACS Chem Neurosci"},{"key":"S0317167124000313_ref25","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/mds.26987","article-title":"Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria","volume":"32","author":"Hoglinger","year":"2017","journal-title":"Mov Disord"},{"key":"S0317167124000313_ref74","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.3233\/JAD-190539","article-title":"Reciprocal incremental value of 18F-FDG-PET and cerebrospinal fluid biomarkers in mild cognitive impairment patients suspected for Alzheimer\u2019s disease and inconclusive first biomarker","volume":"72","author":"Massa","year":"2019","journal-title":"J Alzheimers Dis"},{"key":"S0317167124000313_ref64","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jalz.2018.09.003","article-title":"AMYPAD diagnostic and patient management study: rationale and design","volume":"15","author":"Frisoni","year":"2019","journal-title":"Alzheimers Dement"},{"key":"S0317167124000313_ref48","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.neurobiolaging.2016.07.012","article-title":"Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer\u2019s disease in the context of a structured 5-phase development framework","volume":"52","author":"Chiotis","year":"2017","journal-title":"Neurobiol Aging"},{"key":"S0317167124000313_ref46","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"key":"S0317167124000313_ref91","article-title":"PET imaging of neuro-inflammation with tracers targeting the translocator protein (TSPO), a systematic review: from bench to bedside","volume":"13","author":"Corica","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"S0317167124000313_ref32","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1002\/alz.12294","article-title":"Associations among education, age, and the dementia with Lewy bodies (DLB) metabolic pattern: a European-DLB consortium project","volume":"17","author":"Bauckneht","year":"2021","journal-title":"Alzheimers Dement"},{"key":"S0317167124000313_ref31","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.pscychresns.2004.07.006","article-title":"Hemispheric asymmetries of hypometabolism associated with semantic memory impairment in Alzheimer\u2019s disease: a study using positron emission tomography with fluorodeoxyglucose-F18","volume":"15","author":"Zahn","year":"2004","journal-title":"Psychiatr Res Neuroimag"},{"key":"S0317167124000313_ref14","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2967\/jnumed.109.065870","article-title":"The 18F-FDG PET cingulate island sign and comparison to 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies","volume":"50","author":"Lim","year":"2009","journal-title":"J Nuclear Med"},{"key":"S0317167124000313_ref77","doi-asserted-by":"crossref","first-page":"e12068","DOI":"10.1002\/trc2.12068","article-title":"CCCDTD5 recommendations on early non cognitive markers of dementia: a Canadian consensus","volume":"6","author":"Montero-Odasso","year":"2020","journal-title":"Alzheimers Dement (N Y)"},{"key":"S0317167124000313_ref73","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s00259-019-04466-6","article-title":"Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer\u2019s disease","volume":"47","author":"Ramusino","year":"2020","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"S0317167124000313_ref95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-016-0009-6","article-title":"In situ click chemistry generation of cyclooxygenase-2 inhibitors","volume":"8","author":"Bhardwaj","year":"2017","journal-title":"Nat Commun"},{"key":"S0317167124000313_ref60","unstructured":"60. CAG-00431R Decision Memo. https:\/\/www.cms.gov\/medicare-coverage-database\/view\/ncacal-decision-memo.aspx?proposed=N&NCAId=308. Accessed October 13, 2023."},{"key":"S0317167124000313_ref103","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27238529","article-title":"PET imaging of fructose metabolism in a rodent model of neuroinflammation with 6-[(18)F]fluoro-6-deoxy-D-fructose","volume":"27","author":"Boyle","year":"2022","journal-title":"Molecules"},{"key":"S0317167124000313_ref1","unstructured":"1. https:\/\/www.alzint.org\/about\/dementia-facts-figures\/dementia-statistics\/. Accessed February 02, 2024."},{"key":"S0317167124000313_ref19","doi-asserted-by":"crossref","first-page":"702639","DOI":"10.3389\/fnagi.2021.702639","article-title":"Alpha-synuclein as a biomarker of parkinson\u2019s disease: good, but not good enough","volume":"13","author":"Ganguly","year":"2021","journal-title":"Front Aging Neurosci"},{"key":"S0317167124000313_ref9","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1474-4422(17)30159-X","article-title":"Strategic roadmap for an early diagnosis of Alzheimer\u2019s disease based on biomarkers","volume":"16","author":"Frisoni","year":"2017","journal-title":"Lancet Neurol"},{"key":"S0317167124000313_ref21","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the national institute on aging-Alzheimer\u2019s association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"key":"S0317167124000313_ref47","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimer\u2019s disease with Pittsburgh compound-B","volume":"55","author":"Klunk","year":"2004","journal-title":"Ann Neurol"},{"key":"S0317167124000313_ref94","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1096\/fj.14-268714","article-title":"The P2X7 receptor directly interacts with the NLRP3 inflammasome scaffold protein","volume":"29","author":"Franceschini","year":"2015","journal-title":"FASEB J"},{"key":"S0317167124000313_ref118","doi-asserted-by":"crossref","first-page":"100982","DOI":"10.1016\/j.xcrm.2023.100982","article-title":"Lecanemab reduces brain amyloid-beta and delays cognitive worsening","volume":"4","author":"Knopman","year":"2023","journal-title":"Cell Rep Med"},{"key":"S0317167124000313_ref102","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/(SICI)1098-1136(199711)21:3<327::AID-GLIA7>3.0.CO;2-1","article-title":"Glucose transporter glut 5 expression in microglial cells","volume":"21","author":"Payne","year":"1997","journal-title":"Glia"},{"key":"S0317167124000313_ref110","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1001\/jamaneurol.2015.1807","article-title":"Nerve growth factor gene therapy: activation of neuronal responses in alzheimer disease","volume":"72","author":"Tuszynski","year":"2015","journal-title":"JAMA Neurol"},{"key":"S0317167124000313_ref76","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/ene.14117","article-title":"Italian consensus recommendations for a biomarker-based aetiological diagnosis in mild cognitive impairment patients","volume":"27","author":"Boccardi","year":"2020","journal-title":"Eur J Neurol"},{"key":"S0317167124000313_ref87","doi-asserted-by":"crossref","DOI":"10.1002\/alz.065394","article-title":"Initial clinical scans using [18-F]-ACI-12589, a novel \u03b1-synuclein PET-tracer","volume":"18","author":"Smith","year":"2022","journal-title":"Alzheimer\u2019s Dement"},{"key":"S0317167124000313_ref44","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s41824-020-00093-9","article-title":"11C-UCB-J synaptic PET and multimodal imaging in dementia with Lewy bodies","volume":"4","author":"Nicastro","year":"2020","journal-title":"Eur J Hybrid Imaging"},{"key":"S0317167124000313_ref7","doi-asserted-by":"crossref","first-page":"103204","DOI":"10.1016\/j.nicl.2022.103204","article-title":"White matter hyperintensity distribution differences in aging and neurodegenerative disease cohorts","volume":"36","author":"Dadar","year":"2022","journal-title":"Neuroimage Clin"},{"key":"S0317167124000313_ref16","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1192\/bjp.bp.108.052050","article-title":"Diagnostic accuracy of 123I-FP-CIT SPECT in possible dementia with Lewy bodies","volume":"194","author":"O\u2019Brien","year":"2009","journal-title":"Br J Psychiatry"},{"key":"S0317167124000313_ref58","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1055\/a-1277-6014","article-title":"Appropriate use criteria for dementia amyloid imaging in Switzerland - mini-review and statement on behalf of the swiss society of nuclear medicine and the swiss memory clinics","volume":"60","author":"Juengling","year":"2021","journal-title":"Nuklearmed NuclearMed"},{"key":"S0317167124000313_ref71","unstructured":"71. https:\/\/clinicaltrials.gov\/search?locStr=Canada&country=Canada&term=Tau%20PET. Accessed February 2, 2024."},{"key":"S0317167124000313_ref5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"New Engl J Med"},{"key":"S0317167124000313_ref65","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1093\/brain\/awab248","article-title":"Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages","volume":"144","author":"Pascoal","year":"2021","journal-title":"Brain"},{"key":"S0317167124000313_ref50","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1007\/s00259-019-04596-x","article-title":"A new centiloid method for (18)F-florbetaben and (18)F-flutemetamol PET without conversion to PiB","volume":"47","author":"Cho","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"S0317167124000313_ref120","doi-asserted-by":"crossref","first-page":"562","DOI":"10.2214\/AJR.22.28461","article-title":"Amyloid-related imaging Abnormalities: an update","volume":"220","author":"Roytman","year":"2023","journal-title":"AJR Am J Roentgenol"},{"key":"S0317167124000313_ref52","first-page":"1233","article-title":"Standardized expression of 18F-NAV4694 and 11C-PiB \u03b2-amyloid PET results with the centiloid scale","volume":"1","author":"Rowe","year":"2016","journal-title":"JNuclear Med"},{"key":"S0317167124000313_ref96","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1021\/acs.molpharmaceut.9b00986","article-title":"Radiosynthesis and biological evaluation of [(18)F]Triacoxib: a new radiotracer for PET imaging of COX-2","volume":"17","author":"Litchfield","year":"2020","journal-title":"Mol Pharm"},{"key":"S0317167124000313_ref57","unstructured":"57. FDA. Drugs@FDA: FDA-Approved Drugs, Aduhelm - Aducanumab-AVWA. June 07, 2021. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&varApplNo=761178. Accessed June 04, 2023."},{"key":"S0317167124000313_ref97","doi-asserted-by":"crossref","first-page":"890425","DOI":"10.3389\/fneur.2022.890425","article-title":"Simultaneous PET\/MRI:The future gold standard for characterizing motor neuron disease-A clinico-radiological and neuroscientific perspective","volume":"13","author":"Juengling","year":"2022","journal-title":"Front Neurol"},{"key":"S0317167124000313_ref84","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1024\/1661-8157\/a002948","article-title":"Recommendations of Swiss memory clinics for the diagnosis of dementia","volume":"107","author":"Burge","year":"2018","journal-title":"Praxis (Bern 1994)"},{"key":"S0317167124000313_ref49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","article-title":"The centiloid project: standardizing quantitative amyloid plaque estimation by PET","volume":"11","author":"Klunk","year":"2015","journal-title":"Alzheimers Dement"},{"key":"S0317167124000313_ref20","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.jalz.2018.02.015","article-title":"Cerebrospinal fluid alpha-synuclein contributes to the differential diagnosis of Alzheimer\u2019s disease","volume":"14","author":"Shi","year":"2018","journal-title":"Alzheimers Dement"},{"key":"S0317167124000313_ref30","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1162\/jocn.2006.18.12.2138","article-title":"Patterns of regional brain hypometabolism associated with knowledge of semantic features and categories in Alzheimer\u2019s disease","volume":"18","author":"Zahn","year":"2006","journal-title":"J Cognit Neurosci"},{"key":"S0317167124000313_ref108","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1021\/acs.jmedchem.7b01607","article-title":"Identification of [18F]TRACK, a fluorine-18-labeled tropomyosin receptor kinase (Trk) inhibitor for PET imaging","volume":"22","author":"Bernard-Gauthier","year":"2018","journal-title":"J Med Chem"},{"key":"S0317167124000313_ref3","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer\u2019s disease","volume":"6","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"key":"S0317167124000313_ref106","doi-asserted-by":"crossref","first-page":"560865","DOI":"10.3389\/fnagi.2020.560865","article-title":"Cerebral fructose metabolism as a potential mechanism driving Alzheimer\u2019s disease","volume":"12","author":"Johnson","year":"2020","journal-title":"Front Aging Neurosci"},{"key":"S0317167124000313_ref8","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1080\/21678421.2020.1727926","article-title":"Spectroscopic markers of neurodegeneration in the mesial prefrontal cortex predict survival in ALS","volume":"21","author":"Hanstock","year":"2020","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"S0317167124000313_ref35","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1021\/acschemneuro.8b00526","article-title":"Synthesis and in vivo evaluation of a novel PET radiotracer for imaging of synaptic vesicle glycoprotein 2A (SV2A) in nonhuman primates","volume":"10","author":"Li","year":"2019","journal-title":"ACS Chem Neurosci"},{"key":"S0317167124000313_ref18","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41531-022-00357-0","article-title":"Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson\u2019s disease and other synucleinopathies","volume":"8","author":"Magalhaes","year":"2022","journal-title":"NPJ Parkinsons Dis"},{"key":"S0317167124000313_ref26","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","article-title":"Second consensus statement on the diagnosis of multiple system atrophy","volume":"71","author":"Gilman","year":"2008","journal-title":"Neurology"},{"key":"S0317167124000313_ref82","first-page":"1","volume-title":"Rapid synthesis: Examining the public provision and funding of PET-CT imaging for non-cancer indications","author":"Mattison","year":"2018"},{"key":"S0317167124000313_ref90","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s11307-022-01779-1","article-title":"Head-to-head comparison of tau-PET radioligands for imaging TDP-43 in post-mortem ALS brain","volume":"25","author":"Knight","year":"2023","journal-title":"Mol Imaging Biol"},{"key":"S0317167124000313_ref115","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1001\/jamaneurol.2022.4485","article-title":"Association of phosphorylated tau biomarkers with amyloid positron emission tomography vs tau positron emission tomography","volume":"1","author":"Therriault","year":"2023","journal-title":"JAMA Neurol"},{"key":"S0317167124000313_ref27","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s00259-015-3098-2","article-title":"A cochrane review on brain [(1)(8)F]FDG PET in dementia: limitations and future perspectives","volume":"42","author":"Morbelli","year":"2015","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"S0317167124000313_ref67","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1001\/jamaneurol.2020.0528","article-title":"Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of alzheimer disease neuropathologic changes","volume":"77","author":"Fleisher","year":"2020","journal-title":"JAMA Neurol"},{"key":"S0317167124000313_ref117","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer\u2019s disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"key":"S0317167124000313_ref59","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00259-022-06025-y","article-title":"Positive opinion of the french national authority for health on the reimbursement of amyloid tracer (Flutemetamol)","volume":"50","author":"Garnier-Crussard","year":"2023","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"S0317167124000313_ref79","doi-asserted-by":"crossref","first-page":"e12098","DOI":"10.1002\/trc2.12098","article-title":"CCCDTD5: clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment","volume":"6","author":"Brisson","year":"2020","journal-title":"Alzheimers Dement (N Y)"},{"key":"S0317167124000313_ref62","doi-asserted-by":"crossref","first-page":"e12383","DOI":"10.1002\/trc2.12383","article-title":"Patient-related benefits of amyloid PET imaging in dementia: rationale and design of the German randomized coverage with evidence development study ENABLE","volume":"9","author":"Teipel","year":"2023","journal-title":"Alzheimers Dement (N Y)"},{"key":"S0317167124000313_ref88","doi-asserted-by":"crossref","first-page":"6750","DOI":"10.1038\/s41467-023-42305-3","article-title":"The alpha-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases","volume":"14","author":"Smith","year":"2023","journal-title":"Nat Commun"},{"key":"S0317167124000313_ref99","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s12149-018-1290-8","article-title":"CXCR4-directed theranostics in oncology and inflammation","volume":"32","author":"Kircher","year":"2018","journal-title":"Ann Nuclear Med"},{"key":"S0317167124000313_ref122","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/cjn.2023.283","article-title":"Can we improve care of people with mild cognitive impairment or dementia in Canada?","author":"Gauthier","year":"2023","journal-title":"Can J Neurol Sci"},{"key":"S0317167124000313_ref55","doi-asserted-by":"crossref","first-page":"266","DOI":"10.2967\/jnumed.122.264256","article-title":"Early-phase 18F-florbetapir and 18F-flutemetamol images as proxies of brain metabolism in a memory clinic setting","volume":"64","author":"Boccalini","year":"2022","journal-title":"J Nucl Med"},{"key":"S0317167124000313_ref75","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1007\/s00259-020-04969-7","article-title":"Clinical impact of 18F-FDG-PET among memory clinic patients with uncertain diagnosis","volume":"48","author":"Perini","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"S0317167124000313_ref6","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S1474-4422(20)30314-8","article-title":"Amyloid-PET and (18)F-FDG-PET in the diagnostic investigation of Alzheimer\u2019s disease and other dementias","volume":"19","author":"Chetelat","year":"2020","journal-title":"Lancet Neurol"},{"key":"S0317167124000313_ref61","unstructured":"61. First Reimbursed Amyloid PET Diagnostic Tool in Japan. https:\/\/life-mi.com\/cmi-inc-and-life-molecular-imaging-announce-the-reimbursement-of-the-amyloid-pet-diagnostic-neuraceq-florbetaben-18f-in-japan\/. Accessed November 22, 2023."},{"key":"S0317167124000313_ref56","unstructured":"56. FDA. Drugs@FDA: FDA-Approved Drugs: Leqembi - Lecanemab-IRMB. January 6, 2023. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=761269. Accessed June 4, 2023."},{"key":"S0317167124000313_ref98","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1471-2377-6-12","article-title":"COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells\/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord","volume":"6","author":"Yiangou","year":"2006","journal-title":"BMC Neurol"},{"key":"S0317167124000313_ref37","doi-asserted-by":"crossref","first-page":"348ra96","DOI":"10.1126\/scitranslmed.aaf6667","article-title":"Imaging synaptic density in the living human brain","volume":"8","author":"Finnema","year":"2016","journal-title":"Sci Transl Med"},{"key":"S0317167124000313_ref34","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s11307-014-0820-6","article-title":"Biodistribution and radiation dosimetry for the novel SV2A radiotracer [(18)F]UCB-H: first-in-human study","volume":"17","author":"Bretin","year":"2015","journal-title":"Mol Imaging Biol"},{"key":"S0317167124000313_ref40","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.3174\/ajnr.A3113","article-title":"Alzheimer\u2019s disease neuroimaging I. Whither the hippocampus? FDG-PET hippocampal hypometabolism in Alzheimer disease revisited","volume":"33","author":"Maldjian","year":"2012","journal-title":"AJNR Am J Neuroradiol"},{"key":"S0317167124000313_ref111","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1089\/hum.2017.069","article-title":"Design of a novel gene therapy construct to achieve sustained brain-derived neurotrophic factor signaling in neurons","volume":"29","author":"Osborne","year":"2018","journal-title":"Hum Gene Ther"},{"key":"S0317167124000313_ref63","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/jama.2019.2000","article-title":"Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia","volume":"2","author":"Rabinovici","year":"2019","journal-title":"JAMA"},{"key":"S0317167124000313_ref43","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1002\/mds.28617","article-title":"Reduced synaptic density in patients with Lewy body dementia: an [(11) C]UCB-J PET imaging study","volume":"36","author":"Andersen","year":"2021","journal-title":"Mov Disord"},{"key":"S0317167124000313_ref80","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1017\/cjn.2015.401","article-title":"Canadian consensus guidelines on use of amyloid imaging in Canada: update and future directions from the specialized task force on amyloid imaging in Canada","volume":"43","author":"Laforce","year":"2016","journal-title":"Can J Neurol Sci"},{"key":"S0317167124000313_ref114","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1007\/s00259-020-05116-y","article-title":"Molecular imaging and fluid biomarkers of Alzheimer\u2019s disease neuropathology: an opportunity for integrated diagnostics","volume":"48","author":"Garibotto","year":"2021","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"S0317167124000313_ref93","unstructured":"93. Search term: TSPO PET in Canada. https:\/\/clinicaltrials.gov\/search?term=TSPO&locStr=Canada&country=Canada. Accessed February 2, 2024."},{"key":"S0317167124000313_ref2","unstructured":"2. Prince, M , Wimo, A , Guerchet, M , et\u00a0al. World Alzheimer Report 2015 - The global impact of dementia: An analysis of prevalence, incidence, cost and trends. London, UK: Alzheimer\u2019s Disease International, 2015: 1\u201384."},{"key":"S0317167124000313_ref109","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13550-022-00915-w","article-title":"Toward in vivo proof of binding of 18F-labeled inhibitor [(18)F]TRACK to peripheral tropomyosin receptor kinases","volume":"12","author":"Wuest","year":"2022","journal-title":"EJNMMI Res"},{"key":"S0317167124000313_ref116","doi-asserted-by":"crossref","first-page":"e12050","DOI":"10.1002\/trc2.12050","article-title":"Alzheimer\u2019s disease drug development pipeline: 2020","volume":"6","author":"Cummings","year":"2020","journal-title":"Alzheimers Dement (N Y)"},{"key":"S0317167124000313_ref104","first-page":"248","article-title":"Automated synthesis and dosimetry of 6-deoxy-6-[(18)F]fluoro-D-fructose (6-[(18)F]FDF): a radiotracer for imaging of GLUT5 in breast cancer","volume":"4","author":"Bouvet","year":"2014","journal-title":"Am J Nucl Med Mol Imag"},{"key":"S0317167124000313_ref42","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00401-006-0127-z","article-title":"Staging of alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry","volume":"112","author":"Braak","year":"2006","journal-title":"Acta Neuropathol"},{"key":"S0317167124000313_ref89","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.mcn.2018.10.003","article-title":"Biomarkers for diseases with TDP-43 pathology","volume":"97","author":"Steinacker","year":"2019","journal-title":"Mol Cell Neurosci"},{"key":"S0317167124000313_ref101","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1177\/1073858416685690","article-title":"CXCL12\/CXCR4\/CXCR7 chemokine axis in the central nervous system: therapeutic targets for remyelination in demyelinating diseases","volume":"23","author":"Chu","year":"2017","journal-title":"Neuroscientist"},{"key":"S0317167124000313_ref70","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222313002","article-title":"Tau biomarkers in dementia: positron emission tomography radiopharmaceuticals in tauopathy assessment and future perspective","volume":"22","author":"Ricci","year":"2021","journal-title":"Int J Mol Sci"},{"key":"S0317167124000313_ref39","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jagp.2023.08.002","article-title":"Assessment of gray matter microstructure and synaptic density in Alzheimer\u2019s disease: a multimodal imaging study with DTI and SV2A PET","volume":"32","author":"Silva-Rudberg","year":"2024","journal-title":"Am J Geriatr Psychiatry"},{"key":"S0317167124000313_ref72","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1007\/s00259-021-05246-x","article-title":"Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison","volume":"48","author":"Altomare","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"S0317167124000313_ref68","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/alz.13355","article-title":"The impact of tau deposition and hypometabolism on cognitive impairment and longitudinal cognitive decline","volume":"20","author":"Boccalini","year":"2024","journal-title":"Alzheimers Dement"},{"key":"S0317167124000313_ref36","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1021\/acschemneuro.9b00618","article-title":"Synthesis and preclinical evaluation of an 18F-labeled synaptic vesicle glycoprotein 2A PET imaging probe: [18F]SynVesT-2","volume":"11","author":"Cai","year":"2020","journal-title":"ACS Chem Neurosci"},{"key":"S0317167124000313_ref54","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.nicl.2016.10.005","article-title":"Evaluation of early-phase [18F]-florbetaben PET acquisition in clinical routine cases","volume":"14","author":"Daerr","year":"2017","journal-title":"Neuroimage Clin"},{"key":"S0317167124000313_ref86","doi-asserted-by":"crossref","DOI":"10.3390\/ph14090847","article-title":"Alpha-synuclein PET tracer development-an overview about current efforts","volume":"14","author":"Korat","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"S0317167124000313_ref112","unstructured":"112. Search term: 18F-TRACK PET in Canada. https:\/\/clinicaltrials.gov\/search?term=TSPO&locStr=Canada&country=Canada. Accessed February 2, 2024."},{"key":"S0317167124000313_ref78","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/alz.12105","article-title":"Recommendations of the 5th Canadian consensus conference on the diagnosis and treatment of dementia","volume":"16","author":"Ismail","year":"2020","journal-title":"Alzheimers Dement"},{"key":"S0317167124000313_ref22","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the national institute on aging-Alzheimer\u2019s association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement"},{"key":"S0317167124000313_ref69","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.dadm.2018.01.007","article-title":"Tau positron emission tomography imaging in tauopathies: the added hurdle of off-target binding","volume":"10","author":"Lemoine","year":"2018","journal-title":"Alzheimers Dement (Amst)"},{"key":"S0317167124000313_ref17","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1212\/WNL.55.10.1575","article-title":"18F-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with Lewy bodies","volume":"55","author":"Hu","year":"2000","journal-title":"Neurology"},{"key":"S0317167124000313_ref24","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","article-title":"Criteria for the diagnosis of corticobasal degeneration","volume":"80","author":"Armstrong","year":"2013","journal-title":"Neurology"},{"key":"S0317167124000313_ref10","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1148\/radiol.2020200028","article-title":"Molecular imaging approaches in dementia","volume":"298","author":"Villemagne","year":"2021","journal-title":"Radiology"},{"key":"S0317167124000313_ref4","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/alz.12286","article-title":"ENGAGE and EMERGE: truth and consequences?","volume":"17","author":"Kuller","year":"2021","journal-title":"Alzheimer\u2019s Dement"},{"key":"S0317167124000313_ref13","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.pscychresns.2005.08.001","article-title":"Mapping of temporal and parietal cortex in progressive nonfluent aphasia and Alzheimer\u2019s disease using chemical shift imaging, voxel-based morphometry and positron emission tomography","volume":"30","author":"Zahn","year":"2005","journal-title":"Psychiatr Res Neuroimag"},{"key":"S0317167124000313_ref81","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1007\/s00259-020-04817-8","article-title":"EANM practice guideline\/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0","volume":"47","author":"Morbelli","year":"2020","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"S0317167124000313_ref41","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1001\/jamaneurol.2018.1836","article-title":"Assessing synaptic density in Alzheimer disease with synaptic vesicle glycoprotein 2A positron emission tomographic imaging","volume":"75","author":"Chen","year":"2018","journal-title":"JAMA Neurol"},{"key":"S0317167124000313_ref119","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1093\/brain\/awad188","article-title":"Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics","volume":"146","author":"Hampel","year":"2023","journal-title":"Brain"},{"key":"S0317167124000313_ref23","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1093\/brain\/awr179","article-title":"Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia","volume":"134","author":"Rascovsky","year":"2011","journal-title":"Brain"},{"key":"S0317167124000313_ref15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.neurobiolaging.2020.12.009","article-title":"The value of multimodal imaging with (123)I-FP-CIT SPECT in differential diagnosis of dementia with Lewy bodies and Alzheimer\u2019s disease dementia","volume":"99","author":"Miyagawa","year":"2021","journal-title":"Neurobiol Aging"},{"key":"S0317167124000313_ref100","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1007\/s10753-015-0109-1","article-title":"The anti-inflammatory effect of the CXCR4 antagonist-N15P peptide and its modulation on inflammation-associated mediators in LPS-induced PBMC","volume":"38","author":"Mo","year":"2015","journal-title":"Inflammation"},{"key":"S0317167124000313_ref33","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.trci.2017.08.004","article-title":"Measuring brain synaptic vesicle protein 2A with positron emission tomography and [18F]UCB-H","volume":"3","author":"Bahri","year":"2017","journal-title":"Alzheimers Dement (N Y)"},{"key":"S0317167124000313_ref83","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/ene.14117","article-title":"Italian consensus recommendations for a biomarker-based aetiological diagnosis in mild cognitive impairment patients","volume":"27","author":"Boccardi","year":"2020","journal-title":"Eur J Neurol"},{"key":"S0317167124000313_ref113","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/alz.12283","article-title":"The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer\u2019s disease","volume":"17","author":"Simren","year":"2021","journal-title":"Alzheimers Dement"},{"key":"S0317167124000313_ref29","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/ana.25453","article-title":"Metabolic patterns across core features in dementia with lewy bodies","volume":"85","author":"Morbelli","year":"2019","journal-title":"Ann Neurol"},{"key":"S0317167124000313_ref38","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/s00259-019-04461-x","article-title":"In vivo imaging of synaptic loss in Alzheimer\u2019s disease with [18F]UCB-H positron emission tomography","volume":"47","author":"Bastin","year":"2020","journal-title":"Eu J Nuclear Med Molecul Imag"},{"key":"S0317167124000313_ref92","doi-asserted-by":"crossref","first-page":"4862","DOI":"10.2174\/0929867329666220329204054","article-title":"Essential principles and recent progress in the development of TSPO PET ligands for neuroinflammation imaging","volume":"6","author":"Viviano","year":"2022","journal-title":"Curr Med Chem"}],"container-title":["Canadian Journal of Neurological Sciences \/ Journal Canadien des Sciences Neurologiques"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0317167124000313","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T01:51:57Z","timestamp":1767837117000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0317167124000313\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,4]]},"references-count":122,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0317167124000313"],"URL":"https:\/\/doi.org\/10.1017\/cjn.2024.31","relation":{},"ISSN":["0317-1671","2057-0155"],"issn-type":[{"value":"0317-1671","type":"print"},{"value":"2057-0155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,4]]}}}